B-cell acute lymphoblastic leukaemia
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa
The new formulation would allow blood cancer patients to halve their daily pill intake
GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma
Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year
J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma
More than 35,000 people in the EU were diagnosed with the blood cancer in 2022
Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer
Up to 160,000 people in the US are affected by polycythaemia vera
Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma
Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease
Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication
B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases
AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn
SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer
ICR researchers identify potential treatment approach for acute myeloid leukaemia
More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year
BeiGene’s Brukinsa recommended by NICE to treat marginal zone lymphoma
Approximately 2,600 cases of the blood cancer are diagnosed in the UK every year
Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication
More than 6,500 new cases of the blood cancer were diagnosed in the US last year